Cargando…
Prospective Attitudes towards Respiratory Syncytial Virus (RSV) Vaccination: Validation of a Survey Instrument among Young Females in Jordan Pending Vaccine Authorization
In May 2023, the U.S. FDA advisors endorsed Pfizer’s pregnancy-administered vaccine (branded ABRYSVO) to protect infants from respiratory syncytial virus (RSV) infection. Vaccination can reduce the burden of RSV-related respiratory disease, with previous studies showing its substantial medical and f...
Autores principales: | Kherfan, Tleen, Sallam, Malik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459998/ https://www.ncbi.nlm.nih.gov/pubmed/37631954 http://dx.doi.org/10.3390/vaccines11081386 |
Ejemplares similares
-
Strategic priorities for respiratory syncytial virus (RSV) vaccine development
por: Anderson, L.J., et al.
Publicado: (2013) -
Attitude towards HPV Vaccination and the Intention to Get Vaccinated among Female University Students in Health Schools in Jordan
por: Sallam, Malik, et al.
Publicado: (2021) -
Respiratory Syncytial Virus (RSV)
por: Walsh, Edward E., et al.
Publicado: (2015) -
Influenza and respiratory syncytial virus (RSV) vaccines for infants: Safety, immunogenicity, and efficacy
por: Beeler, Judy A., et al.
Publicado: (2013) -
M Protein-Deficient Respiratory Syncytial Virus (RSV) Vaccine Protects Infant Baboons Against RSV Challenge
por: Welliver, Robert C, et al.
Publicado: (2017)